Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17438890 | 0.89 | OPRM1 (0.54) | OPRM1OPRL1CYP3A4CYP2D6TSHR | |
| SCHEMBL17438983 | 0.86 | OPRM1 (0.52) | OPRM1OPRL1CYP3A4TSHRCYP2C19 | |
| SCHEMBL17438597 | 0.86 | OPRM1 (0.69) | OPRM1OPRL1 | |
| SCHEMBL17439088 | 0.85 | OPRM1 (0.51) | OPRM1OPRL1CYP3A4CYP2D6TSHR | |
| SCHEMBL17439157 | 0.85 | OPRM1 (0.56) | OPRM1OPRL1CYP3A4CYP2D6HIF1A | |
| SCHEMBL17438698 | 0.85 | OPRM1 (0.69) | OPRM1OPRL1ALDH1A1 | |
| SCHEMBL17438724 | 0.85 | OPRM1 (0.55) | OPRM1OPRL1TSHR | |
| SCHEMBL17439158 | 0.85 | OPRM1 (0.52) | OPRM1OPRL1 | |
| SCHEMBL17438676 | 0.85 | OPRM1 (0.57) | OPRM1OPRL1CYP3A4TSHRCYP2C19 | |
| SCHEMBL17439110 | 0.84 | OPRM1 (0.52) | OPRM1OPRL1CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885OPRL1 1/4885CYP3A4 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.